HomeCompareBICTF vs VIG

BICTF vs VIG: Dividend Comparison 2026

BICTF yields 20000.00% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BICTF wins by $52481917574412746752.00M in total portfolio value
10 years
BICTF
BICTF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full BICTF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — BICTF vs VIG

📍 BICTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBICTFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BICTF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BICTF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BICTF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, BICTF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BICTF + VIG for your $10,000?

BICTF: 50%VIG: 50%
100% VIG50/50100% BICTF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BICTF buys
0
VIG buys
0
No recent congressional trades found for BICTF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBICTFVIG
Forward yield20000.00%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52481917574412746752.00M$32.4K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$179.15
Total dividends collected$52448189483771600896.00M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BICTF vs VIG ($10,000, DRIP)

YearBICTF PortfolioBICTF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,304$163.92+$2.00MBICTF
2$377,983,225$375,831,775.70$12,759$166.33+$377.97MBICTF
3$66,433,479,469$66,029,037,418.28$14,382$168.52+$66433.47MBICTF
4$10,916,985,471,987$10,845,901,648,955.73$16,192$170.52+$10916985.46MBICTF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$18,210$172.34+$1677384363.75MBICTF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$20,460$173.98+$240985175079.12MBICTF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$22,968$175.48+$32373573631143.67MBICTF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$25,763$176.83+$4066766648320630.00MBICTF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$28,878$178.05+$477730483406513344.00MBICTF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$32,350$179.15+$52481917574412746752.00MBICTF

BICTF vs VIG: Complete Analysis 2026

BICTFStock

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Full BICTF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BICTF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BICTF vs SCHDBICTF vs JEPIBICTF vs OBICTF vs KOBICTF vs MAINBICTF vs DGROBICTF vs NOBLBICTF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.